1. Kim JH, Ye YM, Ban GY, Shin YS, Lee HY, Nam YH, et al. Effects of immunoglobulin replacement on asthma exacerbation in adult asthmatics with IgG subclass deficiency. Allergy Asthma Immunol Res. 2017; 9:526–533.
Article
2. Cho YS. Effective strategies for managing asthma exacerbations for precision medicine. Allergy Asthma Immunol Res. 2017; 9:463–465.
Article
3. Hojo M, Ohta K, Iikura M, Hirashima J, Sugiyama H, Takahashi K. The impact of co-existing seasonal allergic rhinitis caused by Japanese cedar pollinosis (SAR-JCP) upon asthma control status. Allergol Int. 2015; 64:150–155.
Article
4. Okamoto Y, Okubo K, Yonekura S, Hashiguchi K, Goto M, Otsuka T, et al. Efficacy and safety of sublingual immunotherapy for two seasons in patients with Japanese cedar pollinosis. Int Arch Allergy Immunol. 2015; 166:177–188.
Article
5. Yamanaka K, Shah SA, Sakaida H, Yamagiwa A, Masuda S, Mizutani H, et al. Immunological parameters in prophylactic sublingual immunotherapy in asymptomatic subjects sensitized to Japanese cedar pollen. Allergol Int. 2015; 64:54–59.
Article
6. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009; 180:59–99.
7. Marogna M, Spadolini I, Massolo A, Berra D, Zanon P, Chiodini E, et al. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann Allergy Asthma Immunol. 2009; 102:69–75.